These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 7535930)
1. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Gu Z; Arts EJ; Parniak MA; Wainberg MA Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2760-4. PubMed ID: 7535930 [TBL] [Abstract][Full Text] [Related]
2. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567 [TBL] [Abstract][Full Text] [Related]
3. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Ueno T; Mitsuya H Biochemistry; 1997 Feb; 36(5):1092-9. PubMed ID: 9033399 [TBL] [Abstract][Full Text] [Related]
4. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. Arion D; Borkow G; Gu Z; Wainberg MA; Parniak MA J Biol Chem; 1996 Aug; 271(33):19860-4. PubMed ID: 8702696 [TBL] [Abstract][Full Text] [Related]
5. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Zhang D; Caliendo AM; Eron JJ; DeVore KM; Kaplan JC; Hirsch MS; D'Aquila RT Antimicrob Agents Chemother; 1994 Feb; 38(2):282-7. PubMed ID: 7514856 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Faraj A; Agrofoglio LA; Wakefield JK; McPherson S; Morrow CD; Gosselin G; Mathe C; Imbach JL; Schinazi RF; Sommadossi JP Antimicrob Agents Chemother; 1994 Oct; 38(10):2300-5. PubMed ID: 7530932 [TBL] [Abstract][Full Text] [Related]
7. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. Arts EJ; Marois JP; Gu Z; Le Grice SF; Wainberg MA J Virol; 1996 Feb; 70(2):712-20. PubMed ID: 8551607 [TBL] [Abstract][Full Text] [Related]
8. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362 [TBL] [Abstract][Full Text] [Related]
9. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase. Anderson KS Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471 [TBL] [Abstract][Full Text] [Related]
10. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. Arts EJ; Li X; Gu Z; Kleiman L; Parniak MA; Wainberg MA J Biol Chem; 1994 May; 269(20):14672-80. PubMed ID: 7514178 [TBL] [Abstract][Full Text] [Related]
11. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site. Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626 [TBL] [Abstract][Full Text] [Related]
12. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. Ueno T; Shirasaka T; Mitsuya H J Biol Chem; 1995 Oct; 270(40):23605-11. PubMed ID: 7559526 [TBL] [Abstract][Full Text] [Related]
13. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Fan N; Rank KB; Slade DE; Poppe SM; Evans DB; Kopta LA; Olmsted RA; Thomas RC; Tarpley WG; Sharma SK Biochemistry; 1996 Jul; 35(30):9737-45. PubMed ID: 8703945 [TBL] [Abstract][Full Text] [Related]
14. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745 [TBL] [Abstract][Full Text] [Related]
15. Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro. Klarmann GJ; Schauber CA; Preston BD J Biol Chem; 1993 May; 268(13):9793-802. PubMed ID: 7683663 [TBL] [Abstract][Full Text] [Related]
16. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Feng JY; Murakami E; Zorca SM; Johnson AA; Johnson KA; Schinazi RF; Furman PA; Anderson KS Antimicrob Agents Chemother; 2004 Apr; 48(4):1300-6. PubMed ID: 15047533 [TBL] [Abstract][Full Text] [Related]
17. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Shirasaka T; Kavlick MF; Ueno T; Gao WY; Kojima E; Alcaide ML; Chokekijchai S; Roy BM; Arnold E; Yarchoan R Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2398-402. PubMed ID: 7534421 [TBL] [Abstract][Full Text] [Related]